WayPoint Biomedical logo

WayPoint Biomedical(OTC) WYPH

Market Cap$22.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-100%
5 Year-99%
1 Year-71%
1 Month+20%
$0.00
+0.00%
+0.00Today
WayPoint Biomedical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-08
WayPoint Biomedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+20%USD 0.002026-09-08
1 month+20%USD 0.002026-09-08
3 month-53.85%USD 0.002026-06-22
Year to date+100%USD 0.002025-12-29
1 year-71.43%USD 0.002025-10-08
3 year+200%USD 0.002023-09-08
5 year-98.8%USD 0.052021-10-08
Since inception-99.96%USD 1.502005-06-30

WayPoint Biomedical Financials at a Glance

Market Cap

$22.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$0.01

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-2.22 (Low)

Price

$0.00

Volume

22,250

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

WYPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About WayPoint Biomedical

WayPoint Biomedical Holdings, Inc. is a company focused on developing and marketing diagnostic tests and devices aimed at enhancing human health, fitness, and environmental safety. The company operates through its subsidiary, WayPoint Biomedical, Inc., and offers innovative solutions for various markets, including over-the-counter diagnostics and homeland security.

Products and Services
  • Drink Detective test for detecting date rape drugs
  • Health Essist tests for cocaine and marijuana detection
  • Frontline Explosive Test Kit for explosive residue detection
Growth Outlook
  • Expansion into the over-the-counter diagnostic self-testing market
  • Increasing demand for health and safety monitoring solutions
  • Potential partnerships in the homeland security sector
Financial Highlights
  • Recent quarterly net income of -$2,355, reflecting ongoing operational investments
  • Trailing twelve months (TTM) revenue remains at $0, indicating a focus on product development
  • Operating expenses for Q2 2026 were $2,355, showing controlled spending
WayPoint Biomedical Holdings, Inc. is positioned in a niche market with significant growth potential. The company's innovative products address critical health and safety concerns, particularly in the context of rising awareness around personal safety and environmental monitoring. The Drink Detective and Health Essist tests cater to urgent societal needs, while the Frontline Explosive Test Kit aligns with national security priorities. Despite recent financial challenges, including a net income of -$2,355 in the latest quarter, the company is strategically investing in product development and market expansion. The absence of revenue highlights the early-stage nature of the business, focusing on establishing a foothold in the diagnostic and security markets. The controlled operating expenses indicate a commitment to maintaining financial discipline while pursuing growth opportunities. Overall, WayPoint Biomedical Holdings, Inc. presents a compelling case for investors interested in innovative health and safety solutions, with the potential for future growth as the company continues to develop its product offerings and explore new market avenues.
AI Generated • Sep 25, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

John Richer

Headquarters

Huntington Beach, CA 92647, US

WYPH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.42M

Volume

22.25K

Avg. Volume

1.41K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$11.62K

EBITDA

-$11.62K

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

WayPoint Biomedical Performance Analysis

WayPoint Biomedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
WayPoint Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
WayPoint Biomedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD 0.00N/A
20232023-12-31USD 0.00N/A
20242024-12-31USD 0.00N/A
20252025-12-31USD -0.00N/A
WayPoint Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-31N/A
Q12026-03-31N/A
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$22.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$22.50K

N/A

Employees

1

N/A

Net Income

-$2.36K

N/A

EBITDA

-$2.36K

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

0.00%

N/A

Return on Invested Capital

0.00%

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KNKTKunekt Corporation
$0.00+0.00%
BOTHBioethics, Ltd.
$0.01+0.00%
CWNOFChineseworldnet.Com Inc.
$0.00+0.00%
TACITransAtlantic Capital Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$142.52-10.31%
TQQQProShares Trust - ProShares UltraPro Qqq
$80.23-4.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$33.37+4.05%

Questions About WYPH

What is the current price of WayPoint Biomedical?

WayPoint Biomedical is trading at $0.00 per share.

What is the 52-week range for WayPoint Biomedical?

Over the past 52 weeks, WayPoint Biomedical has traded between $0.00 and $0.00.

How much debt does WayPoint Biomedical have?

As of the most recent reporting period, WayPoint Biomedical reported total debt of $0.00.

How much cash does WayPoint Biomedical have on hand?

WayPoint Biomedical reported $0.00 in cash and cash equivalents in its most recent financial results.

What is WayPoint Biomedical’s dividend yield?

WayPoint Biomedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services